With our expertise in the immune system and our high-end serological profiling platform, Oncimmune can provide the following to aid the study of the immune response to vaccines and therapeutics aimed at COVID-19:
Our immuno-assays utilise highly validated technology to study the interaction between a set of antigenic proteins or peptides coupled to magnetic beads incubated with the antibodies in a patient sample. Our immune assays require low sample volumes and allow the measurement of hundreds of peptide and protein antigens simultaneously, making this a valuable tool for high-throughput investigation of protein-antibody interactions of multiple targets at once.
Our bioinformatics and omics-data analysis platforms support large-scale data mining of assay, patient outcome data for creating machine learning models of outcome prediction.
Possible applications through investigation of:
“We’re delighted to offer our laboratory and data analysis capabilities to support our healthcare partners at this important time when the need to develop a vaccine for this highly virulent disease is so high”.
Hans-Dieter Zucht, Head of Technology
Please contact us at firstname.lastname@example.org to find out more.